Community Hospital of the Monterey Peninsula

Community Hospital of the Monterey Peninsula was paid $88.46M by Medicaid between Jan 2018 and Nov 2024, across 337 billing codes. Its largest line is 0121, — 33% of everything it billed.

33Billing provider infoCOMMUNITY HOSPITAL OF THE MONTEREY PENINSULA
MONTEREY, CA 93940

33aNPI1932197258assigned 10/11/2005

33bProvider typeGeneral Acute Care Hospital

28Total paid$88.46M

24GClaims1,096,911

24DCodes billed337

24AFirst – last monthJan 2018 – Nov 2024

Compared with peers

Next to other General Acute Care Hospital providers in California

Rank by total paid#28 of 410

Median peer was paid$6.90M

This provider vs. median13×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	124,755	$6.33M
2019	140,204	$9.57M
2020	125,359	$11.46M
2021	156,309	$12.40M
2022	183,648	$15.42M
2023	192,119	$17.96M
2024incomplete	174,517	$15.32M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
0121		33%	3,381	3,268	$28.88M
0214		19%	2,428	2,369	$16.55M
99281	Emergency department visit for the evaluation and management, self-limited or minor	7.9%	95,879	83,226	$6.98M
97530	Therapeutic activities, direct patient contact, each 15 minutes	2.7%	69,987	22,625	$2.36M
74177	Computed tomography, abdomen and pelvis; with contrast material	2.4%	8,038	7,705	$2.14M
99460		1.8%	459	437	$1.62M
70450	Computed tomography, head or brain; without contrast material	1.4%	5,883	5,440	$1.23M
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	1.3%	8,431	8,275	$1.13M
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	1.2%	9,852	9,211	$1.08M
93975		1.2%	3,544	3,334	$1.06M
77067	Screening mammography, bilateral, including computer-aided detection	1.2%	6,211	6,179	$1.04M
72148	Magnetic resonance imaging, lumbar spine; without contrast material	1.1%	1,626	1,299	$1.00M

325 more codes

96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	1.1%	11,965	$991K
99285	Emergency room visit (most serious)	1.1%	5,969	$974K
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	1.0%	996	$908K
70551	Magnetic resonance imaging, brain; without contrast material	<1%	1,554	$814K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	21,367	$805K
96361	Intravenous infusion, hydration; each additional hour	<1%	13,240	$721K
99283	Emergency room visit (moderate)	<1%	9,451	$686K
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	<1%	4,031	$637K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	1,832	$614K
99243		<1%	8,753	$597K
78815	Positron emission tomography (PET) for limited area imaging	<1%	340	$587K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	7,710	$543K
76700	Ultrasound, abdominal, real time with image documentation; complete	<1%	4,062	$487K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	9,710	$477K
80053	Comprehensive metabolic panel	<1%	56,913	$458K
71046	Radiologic examination, chest; 2 views	<1%	14,835	$446K
71275	Computed tomographic angiography, chest, with contrast material	<1%	1,730	$426K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	6,114	$411K
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	5,157	$410K
96375	Therapeutic injection; each additional sequential IV push	<1%	7,236	$408K
72125	Computed tomography, cervical spine; without contrast material	<1%	1,353	$386K
76830	Ultrasound, transvaginal	<1%	3,732	$374K
71250		<1%	1,606	$372K
97799		<1%	8,237	$368K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	62,309	$368K
76641		<1%	3,321	$319K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	13,413	$296K
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	2,741	$253K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	2,789	$251K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	6,060	$241K
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	<1%	1,039	$237K
77066	Tomosynthesis, mammo	<1%	1,353	$228K
G0108	Diabetes outpatient self-management training services, individual, per 30 minutes	<1%	2,632	$221K
93971		<1%	1,626	$218K
72141		<1%	332	$205K
84443	Thyroid stimulating hormone (TSH)	<1%	15,411	$200K
93000		<1%	2,668	$198K
74150		<1%	564	$193K
T1999	Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks"	<1%	98,830	$187K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	5,460	$167K
73721	Magnetic resonance imaging, any joint of lower extremity; without contrast material	<1%	352	$152K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	1,559	$152K
76770		<1%	1,477	$150K
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	1,262	$148K
77063	Screening digital breast tomosynthesis, bilateral	<1%	3,607	$142K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	6,083	$139K
95810	Polysomnography; sleep staging with 4 or more additional parameters	<1%	358	$137K
97802		<1%	785	$131K
84484		<1%	15,309	$121K
71045	Radiologic examination, chest; single view	<1%	8,236	$111K
80061	Lipid panel	<1%	10,362	$111K
76536		<1%	1,305	$100K
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder	<1%	2,588	$92K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	3,256	$92K
70496		<1%	409	$88K
73564		<1%	2,172	$88K
93970		<1%	482	$88K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	2,959	$87K
76801		<1%	1,073	$86K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	2,485	$85K
87086	Culture, bacterial; quantitative colony count, urine	<1%	12,868	$82K
73030		<1%	2,140	$82K
93017		<1%	1,588	$82K
97803		<1%	575	$81K
73610		<1%	1,923	$79K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	2,408	$78K
73630		<1%	2,049	$78K
81001		<1%	31,238	$77K
83690		<1%	14,521	$77K
72110		<1%	953	$73K
0450	Emergency room services	<1%	6,909	$71K
83036	Hemoglobin; glycosylated (A1C)	<1%	9,148	$69K
90832	Psychotherapy session, about 30 minutes	<1%	675	$65K
97165		<1%	1,001	$63K
93015		<1%	278	$62K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	14,385	$58K
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	<1%	298	$57K
72100		<1%	1,384	$53K
80048	Basic metabolic panel (calcium, ionized)	<1%	8,017	$51K
J7030	Infusion, normal saline solution , 1000 cc	<1%	9,198	$50K
83880		<1%	2,789	$48K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	7,400	$45K
81025		<1%	6,348	$45K
87040		<1%	6,389	$45K
74018		<1%	1,525	$44K
0171	Inj, epinephrine (belcher)	<1%	17	$42K
73502		<1%	1,140	$41K
84466		<1%	3,894	$41K
84439		<1%	5,534	$40K
73130		<1%	1,004	$39K
77080		<1%	750	$38K
70498		<1%	322	$36K
83605		<1%	4,320	$34K
G0475	Hiv antigen/antibody, combination assay, screening	<1%	1,632	$32K
76870		<1%	325	$31K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	891	$31K
85379		<1%	4,059	$31K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	824	$30K
J7050	Infusion, normal saline solution, 250 cc	<1%	5,401	$29K
87088		<1%	4,986	$29K
82728		<1%	2,708	$29K
84145		<1%	1,711	$29K
86140		<1%	7,289	$28K
87186		<1%	4,237	$27K
J2785	Injection, regadenoson, 0.1 mg	<1%	351	$27K
J2270	Injection, morphine sulfate, up to 10 mg	<1%	3,473	$26K
82962		<1%	8,361	$25K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	528	$25K
73110		<1%	711	$24K
90839		<1%	416	$22K
83540		<1%	4,075	$22K
83735		<1%	4,696	$22K
95957		<1%	120	$21K
95811		<1%	57	$20K
99213	Doctor's office visit, returning patient (routine)	<1%	591	$20K
A9502	Technetium tc-99m tetrofosmin, diagnostic, per study dose	<1%	381	$20K
84481		<1%	1,493	$20K
85610		<1%	6,754	$19K
0002A		<1%	480	$19K
72070		<1%	387	$19K
Q3014	Telehealth originating site facility fee	<1%	545	$19K
93010	Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only	<1%	1,525	$19K
85730		<1%	4,824	$18K
86780		<1%	1,577	$16K
73221		<1%	37	$16K
87081		<1%	2,589	$15K
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	<1%	134	$15K
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	<1%	1,156	$14K
96379		<1%	18,211	$14K
86480		<1%	340	$14K
86803		<1%	1,205	$13K
80074		<1%	332	$13K
73560		<1%	400	$12K
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose	<1%	272	$12K
99282	Emergency department visit for the evaluation and management, low to moderate severity	<1%	294	$12K
84153		<1%	915	$12K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	1,137	$12K
86481		<1%	229	$11K
76881		<1%	168	$11K
76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal	<1%	136	$11K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	2,768	$11K
J0780	Injection, prochlorperazine, up to 10 mg	<1%	1,093	$11K
75574		<1%	39	$11K
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	1,958	$11K
82746		<1%	1,018	$11K
J1170	Injection, hydromorphone, up to 4 mg	<1%	1,584	$11K
85652		<1%	5,329	$11K
Z7502		<1%	312	$11K
0001A		<1%	264	$11K
94729		<1%	275	$10K
82565		<1%	2,744	$10K
93042		<1%	591	$10K
86850		<1%	1,516	$9K
84403		<1%	490	$9K
70486		<1%	44	$9K
94060		<1%	262	$9K
95816		<1%	121	$9K
94726		<1%	261	$9K
74183		<1%	31	$9K
94664		<1%	394	$9K
J2060	Injection, lorazepam, 2 mg	<1%	1,875	$9K
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	1,971	$9K
72040		<1%	217	$8K
70491		<1%	27	$8K
87653		<1%	337	$8K
82550		<1%	1,568	$8K
76813		<1%	84	$8K
82043		<1%	1,627	$8K
98960		<1%	160	$8K
72050		<1%	102	$7K
99214	Doctor's office visit, returning patient (more involved)	<1%	177	$7K
73080		<1%	167	$7K
83970		<1%	227	$7K
J2765	Injection, metoclopramide hcl, up to 10 mg	<1%	1,445	$7K
86038		<1%	1,262	$6K
82607		<1%	952	$6K
87340		<1%	776	$6K
86901		<1%	2,579	$6K
86900		<1%	2,578	$6K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	99	$6K
87210		<1%	1,183	$6K
87806		<1%	174	$5K
77049		<1%	12	$5K
73590		<1%	158	$5K
87536		<1%	74	$5K
72131		<1%	14	$5K
87070		<1%	634	$4K
0054A		<1%	108	$4K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	912	$4K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	936	$4K
G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)	<1%	101	$4K
0012A		<1%	97	$4K
71101		<1%	79	$4K
77336		<1%	57	$3K
99199	Unlisted special service, procedure or report	<1%	67	$3K
73700		<1%	13	$3K
J7120	Ringers lactate infusion, up to 1000 cc	<1%	619	$3K
0250		<1%	6,528	$3K
74178		<1%	13	$3K
73140		<1%	100	$3K
0270		<1%	2,776	$3K
93246		<1%	153	$3K
74019		<1%	91	$3K
82248		<1%	749	$3K
93350		<1%	27	$3K
93880		<1%	24	$3K
84550		<1%	728	$3K
0949		<1%	4,577	$2K
0300		<1%	6,102	$2K
80069		<1%	323	$2K
86308		<1%	421	$2K
82670		<1%	104	$2K
0301		<1%	6,028	$2K
84270		<1%	114	$2K
82803		<1%	114	$2K
0064A		<1%	44	$2K
87427		<1%	264	$2K
83001		<1%	127	$2K
J2272	Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg	<1%	248	$2K
76805	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation	<1%	13	$2K
87493		<1%	90	$2K
0071A		<1%	39	$2K
73120		<1%	69	$2K
J1630	Injection, haloperidol, up to 5 mg	<1%	262	$2K
84156		<1%	637	$1K
71020		<1%	25	$1K
80076		<1%	227	$1K
0350		<1%	1,304	$1K
99221		<1%	842	$1K
86592		<1%	308	$1K
86431		<1%	332	$1K
J7070	Infusion, d5w, 1000 cc	<1%	237	$1K
0072A		<1%	32	$1K
0352		<1%	1,285	$1K
72082		<1%	12	$1K
84100		<1%	352	$1K
87077		<1%	156	$1K
J3490	Unclassified drugs	<1%	303	$1K
90715		<1%	29	$1K
76642		<1%	13	$1K
0351		<1%	1,003	$1K
72170		<1%	38	$995.92
0402		<1%	825	$975.29
87045		<1%	134	$959.43
Z7610		<1%	101	$940.84
0004A		<1%	23	$920.00
0011A		<1%	23	$920.00
99000		<1%	2,067	$888.82
84450		<1%	193	$807.22
0730		<1%	3,599	$786.17
84075		<1%	186	$776.71
86359		<1%	25	$754.50
82247		<1%	188	$752.12
80055		<1%	12	$751.80
82040		<1%	184	$732.65
82784		<1%	140	$723.10
80164		<1%	80	$718.80
88304		<1%	21	$695.60
84702		<1%	41	$684.96
85044		<1%	164	$609.03
84155		<1%	185	$542.86
83615		<1%	92	$508.28
84703		<1%	710	$500.46
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	15	$495.81
86762		<1%	45	$489.18
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	49	$451.02
83516		<1%	47	$409.02
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	<1%	33	$367.01
0320		<1%	716	$362.73
73090		<1%	13	$295.74
J2919	Injection, methylprednisolone sodium succinate, 5 mg	<1%	70	$286.99
0306		<1%	3,385	$284.51
0272		<1%	1,625	$280.42
86800		<1%	14	$241.50
86706		<1%	28	$233.67
82274		<1%	14	$230.43
0305		<1%	5,303	$228.83
82951		<1%	25	$226.60
86704		<1%	25	$221.72
93016		<1%	13	$212.82
0324		<1%	2,837	$199.25
0258		<1%	3,518	$191.95
80305		<1%	13	$186.68
J3475	Injection, magnesium sulfate, per 500 mg	<1%	54	$170.34
82533		<1%	14	$169.52
J7040	Infusion, normal saline solution, sterile (500 ml = 1 unit)	<1%	35	$157.73
85027		<1%	29	$155.25
36415	Collection of venous blood by venipuncture	<1%	1,762	$139.76
11043		<1%	21	$139.41
J1644	Injection, heparin sodium, per 1000 units	<1%	41	$131.26
82172		<1%	12	$125.98
86200		<1%	27	$123.86
93018		<1%	13	$123.33
82009		<1%	42	$120.97
0255		<1%	2,125	$116.60
82330		<1%	12	$113.90
86160		<1%	19	$98.80
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	<1%	25	$93.10
86635		<1%	14	$88.08
83002		<1%	12	$78.00
84436		<1%	13	$67.10
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	15	$67.09
84132		<1%	27	$64.77
85014		<1%	13	$16.89
J1171	Injection, hydromorphone, 0.1 mg	<1%	14	$12.88
J7613	Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg	<1%	14	$2.07
A9575	Injection, gadoterate meglumine, 0.1 ml	<1%	312	$1.00
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	30	$0.19
0430		0%	844	$0.00
0489		0%	1,392	$0.00
0360		0%	134	$0.00
G8979	Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	125	$0.00
G8978	Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals	0%	99	$0.00
G8990	Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals	0%	13	$0.00
0420		0%	1,883	$0.00
0471		0%	446	$0.00
0710		0%	120	$0.00
0440		0%	597	$0.00
0410		0%	1,154	$0.00
0370		0%	134	$0.00
0611		0%	183	$0.00
J7620	Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme	0%	27	$0.00
0310		0%	36	$0.00
96376		0%	180	$0.00
G8991	Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	13	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMORGAN, MATTHEW (VICE-PRESIDENT, CFO)

Same official

Other billing entities under MORGAN, MATTHEW

Full network →

Provider	Location	Paid
Santa Barbara Cottage Hospital	Santa Barbara, CA	$13.50M
Community Hospital of the Monterey Peninsula	Monterey, CA	$9.95M
Goleta Valley Cottage Hospital	Santa Barbara, CA	$4.72M
Santa Ynez Valley Cottage Hospital, INC	Solvang, CA	$1.67M
Covenant Family Wellness, LLC	Reynoldsburg, OH	$132K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.